Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmunoGen has started patient dosing in a Phase I clinical trial evaluating the company's IMGN388 targeted anticancer compound for the treatment of solid tumors.
Subscribe to our email newsletter
The Phase I trial (Study 201) underway at South Texas Accelerated Research Therapeutics in San Antonio, Texas is designed to assess the tolerability and pharmacokinetics of IMGN388 in patients with solid tumors; efficacy information also will be obtained.
Increasing doses of the compound, administered every three weeks, are to be evaluated in new cohorts of patients with solid tumors until the maximum tolerated dose (MTD) is established and the dose-limiting toxicities are identified.
Once the MTD is established, enrollment will be limited to patients with tumors that are melanomas, sarcomas or those carcinomas that characteristically express the relevant integrin target.
John Lambert, senior vice president and chief scientific officer of ImmunoGen, said: “We believe IMGN388 offers significant promise for the treatment of solid tumors, as the target for this compound is found on many types of solid tumors and also on endothelial cells in the process of forming new blood vessels.”